Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: neurodegenerative disease therapeutics - Neuronascent

Drug Profile

Research programme: neurodegenerative disease therapeutics - Neuronascent

Alternative Names: NNI-362; NNI-370

Latest Information Update: 20 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neuronascent
  • Class Antidementias; Antiparkinsonians; Small molecules
  • Mechanism of Action Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease
  • Research Parkinson's disease

Most Recent Events

  • 20 Nov 2017 NNI 362 is still in preclinical trials for Alzheimer's disease in USA (PO) (Neuronascent pipeline, November 2017)
  • 20 Nov 2017 NNI 370 is still in early research for Parkinson's disease in USA (PO) (Neuronascent pipeline, November 2017)
  • 14 Nov 2017 Neuronascent has composition of matter patent protection for oral neuron regenerative technology in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top